These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19530240)

  • 41. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response.
    Turowec JP; Lau EWT; Wang X; Brown KR; Fellouse FA; Jawanda KK; Pan J; Moffat J; Sidhu SS
    J Biol Chem; 2019 Jan; 294(4):1396-1409. PubMed ID: 30523157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
    Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL
    Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER3 and LINC00052 interplay promotes tumor growth in breast cancer.
    Salameh A; Fan X; Choi BK; Zhang S; Zhang N; An Z
    Oncotarget; 2017 Jan; 8(4):6526-6539. PubMed ID: 28036286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
    Sheng Q; Liu X; Fleming E; Yuan K; Piao H; Chen J; Moustafa Z; Thomas RK; Greulich H; Schinzel A; Zaghlul S; Batt D; Ettenberg S; Meyerson M; Schoeberl B; Kung AL; Hahn WC; Drapkin R; Livingston DM; Liu JF
    Cancer Cell; 2010 Mar; 17(3):298-310. PubMed ID: 20227043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.
    Day KC; Lorenzatti Hiles G; Kozminsky M; Dawsey SJ; Paul A; Broses LJ; Shah R; Kunja LP; Hall C; Palanisamy N; Daignault-Newton S; El-Sawy L; Wilson SJ; Chou A; Ignatoski KW; Keller E; Thomas D; Nagrath S; Morgan T; Day ML
    Cancer Res; 2017 Jan; 77(1):74-85. PubMed ID: 27793843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FGF23 promotes prostate cancer progression.
    Feng S; Wang J; Zhang Y; Creighton CJ; Ittmann M
    Oncotarget; 2015 Jul; 6(19):17291-301. PubMed ID: 26019137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inactivation of neuregulin-1 by nitration.
    Nethery DE; Ghosh S; Erzurum SC; Kern JA
    Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L287-93. PubMed ID: 16980377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
    Lin SH; Cheng CJ; Lee YC; Ye X; Tsai WW; Kim J; Pasqualini R; Arap W; Navone NM; Tu SM; Hu M; Yu-Lee LY; Logothetis CJ
    Oncogene; 2008 Sep; 27(39):5195-203. PubMed ID: 18490922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.
    Jay SM; Kurtagic E; Alvarez LM; de Picciotto S; Sanchez E; Hawkins JF; Prince RN; Guerrero Y; Treasure CL; Lee RT; Griffith LG
    J Biol Chem; 2011 Aug; 286(31):27729-40. PubMed ID: 21622572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative transcriptional study of the effects of high intracellular zinc on prostate carcinoma cells.
    Wong PF; Abubakar S
    Oncol Rep; 2010 Jun; 23(6):1501-16. PubMed ID: 20428803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptomic classification of antitumor agents: application to the analysis of the antitumoral effect of SR31747A.
    Ferrini JB; Jbilo O; Peleraux A; Combes T; Vidal H; Galiegue S; Casellas P
    Gene Expr; 2003; 11(3-4):125-39. PubMed ID: 14686786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3.
    Srinivasan R; Leverton KE; Sheldon H; Hurst HC; Sarraf C; Gullick WJ
    Cell Signal; 2001 May; 13(5):321-30. PubMed ID: 11369513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells.
    Sprenger CC; Drivdahl RH; Woodke LB; Eyman D; Reed MJ; Carter WG; Plymate SR
    Neoplasia; 2008 Dec; 10(12):1350-61. PubMed ID: 19048114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.
    Peess C; von Proff L; Goller S; Andersson K; Gerg M; Malmqvist M; Bossenmaier B; Schräml M
    PLoS One; 2015; 10(2):e0116870. PubMed ID: 25658697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer.
    Nazari M; Minai-Tehrani A; Mousavi S; Zamani Koukhaloo S; Emamzadeh R
    Int J Biol Macromol; 2021 Oct; 189():948-955. PubMed ID: 34455002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7.
    Suga J; Izumiyama K; Tanaka N; Saji S
    Biochem Biophys Rep; 2018 Dec; 16():103-109. PubMed ID: 30417127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma.
    Tanaka Y; Ito T; Kaku-Ito Y; Tanegashima K; Tsuji G; Kido-Nakahara M; Oda Y; Nakahara T
    Cell Death Discov; 2023 Feb; 9(1):54. PubMed ID: 36765036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER3 Alterations in Cancer and Potential Clinical Implications.
    Kilroy MK; Park S; Feroz W; Patel H; Mishra R; Alanazi S; Garrett JT
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuregulin: a cut-and-pasted cancer gene?
    Bradbury J
    Drug Discov Today; 2003 Oct; 8(19):865-6. PubMed ID: 14554006
    [No Abstract]   [Full Text] [Related]  

  • 60. Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3.
    PLOS ONE Editors
    PLoS One; 2022; 17(4):e0267745. PubMed ID: 35468166
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.